The study explores how certain cells in mice that produce insulin (a hormone that regulates blood sugar) migrate to different organs and whether other organs, like the salivary glands, can help in insulin production. Scientists tracked the movement of these insulin-producing cells using genetic labeling techniques.
This study explores the correlation of surrogate measures of insulin resistance (IR) with coronary artery disease (CAD) among patients with type 2 diabetes (T2D). Since direct measures of IR are inconvenient and impractical in clinical settings, the study investigates simpler substitutes, which are triglyceride-glucose index (TyG), TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), TyG-waist-to-height ratio (TyG-WHtR), metabolic score for insulin resistance (METS-IR), and the ratio of triglycerides/high-density lipoprotein cholesterol (TG/HDL-C). Among 2,702 T2D patients, the patients were divided into groups based on CAD status.
The current research examines a novel method for the design of antibody-based drugs against G protein–coupled receptors (GPCRs), proteins involved in numerous physiological processes and often the targets of pharmacological intervention. GPCRs have traditionally been treated with small-molecule drugs; these, however, have the potential to produce unwanted side effects as a result of their lack of specificity. Although antibody-based drugs can potentially be a better option, their design for GPCR targeting is especially challenging as a result of the nature of these proteins.
The study investigates the feasibility, safety, and effectiveness of a high-intensity exercise programme for patients with hypertrophic cardiomyopathy (HCM). Historically, individuals with HCM were advised to avoid intense physical activity due to concerns about sudden cardiac death. However, recent research suggests that exercise might be safer than previously thought, prompting the need for further investigation.
Novo Nordisk has released the findings of its REDEFINE 2 trial, which compared the new weight loss drug, CagriSema, in adults with type 2 diabetes and overweight or obesity. CagriSema consists of two drugs, cagrilintide and semaglutide, aimed at suppressing hunger and weight loss.
